S100A4 Antibody (YA3917)
(Synonyms: 42A; 18A2; CAPL; FSP1; MTS1; P9KA; PEL98)S100A4 Antibody (YA3917) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to S100A4.
-
Host:
Mouse
-
Isotype:
IgG
-
Application:
IHC-P, FC, ELISA
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
Supplied in PBS with 0.05% sodium azide
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
FC
FC: Flow Cytometry
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|
| Dilution Ratio | 1:200-1:1000 | 1:200-1:400 | 1:10000 |
Product Details
S100A4 Antibody (YA3917) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to S100A4.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman, Mouse, Rat
-
Observed Molecular WeightObserved band size: 12 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 12 kDa
Purified recombinant fragment of human S100A4 (AA: 2-101) expressed in E. Coli.
affinity purified.
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS with 0.05% sodium azide
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
S100A4 is a member of the S100 family of low molecular weight calcium-binding proteins that modulate intracellular and extracellular signaling processes[1]. Mechanistically, S100A4 interacts with cytoskeletal elements, including actin and non-muscle myosin, to regulate cell motility, migration, and invasion, contributing to tissue remodeling and metastasis[2][3]. In disease models, S100A4 expression is elevated in fibrotic tissues, various cancers, and neurological disorders, where it promotes progression by activating RAGE-mediated pathways and influencing epithelial-mesenchymal transition[1][3]. Compared with related isoforms such as S100A1 and S100B, S100A4 exhibits lower basal expression in normal tissues but higher inducibility under pathological stress, indicating isoform-specific regulation[1][4]. Experimental inhibition of S100A4 using small-molecule antagonists or peptide-based inhibitors suppresses motility and metastasis in vitro and in vivo, highlighting its utility as a target for translational research[1][5]. For experimental applications, S100A4 can serve as a biomarker for tumor aggressiveness and as a modulator of fibroblast and immune cell function in tissue remodeling assays[1][2]. Collectively, S100A4 represents a distinct functional isoform within the S100 family, integrating calcium-dependent signaling with cytoskeletal regulation and disease pathogenesis.
-
Subcellular Localization
Secreted; Nucleus; Cytoplasm
-
Expression
Tissue_specificity:general expression -
Subunit
Homodimer. Interacts with PPFIBP1 in a calcium-dependent mode (PubMed:11836260). Interacts with PGLYRP1; this complex acts as a chemoattractant that promotes lymphocyte movement (PubMed:26654597, PubMed:30713770). Interacts with MYH9; this interaction increases cell motility (PubMed:16707441). Interacts with Annexin 2/ANXA2 (PubMed:28669632). Interacts with TP53; this interaction promotes TP53 degradation (PubMed:23752197, PubMed:32442400). Interacts with CCR5 (PubMed:30713770). Interacts with FCGR3A; this interaction inhibits PKC-dependent phosphorylation of FCGR3A
-
SwissProt ID
-
Synonyms
42A; 18A2; CAPL; FSP1; MTS1; P9KA; PEL98
Documentation
References
[1]. Delangre E, et al. S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma. Int J Mol Sci. 2022 Sep 20;23(19):11030. [Content Brief]
[2]. Kraus C, et al. S100A1 in cardiovascular health and disease: closing the gap between basic science and clinical therapy. J Mol Cell Cardiol. 2009 Oct;47(4):445-55. [Content Brief]
[3]. Wilder PT, et al. Targeting S100 Calcium-Binding Proteins with Small Molecule Inhibitors. Methods Mol Biol. 2019;1929:291-310. [Content Brief]
[5]. Martínez-Aguilar J, et al. A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours. BMC Cancer. 2015;15:199. [Content Brief]
Powered by Bioz
